Skeletal formula of talsaclidine
Ball-and-stick model of the talsaclidine molecule
Clinical data
ATC code
  • None
Pharmacokinetic data
Protein binding7%
ExcretionRenal (86%)
  • (3R)-3-(Prop-2-yn-1-yloxy)-1-azabicyclo[2.2.2]octane
CAS Number
PubChem CID
CompTox Dashboard (EPA)
ECHA InfoCard100.161.949 Edit this at Wikidata
Chemical and physical data
Molar mass165.236 g·mol−1
3D model (JSmol)
  • O([C@@H]2C1CCN(CC1)C2)CC#C

Talsaclidine (WAL-2014) is a non-selective muscarinic acetylcholine receptor agonist which acts as a full agonist at the M1 subtype, and as a partial agonist at the M2 and M3 subtypes.[1][2][3] It was under development for the treatment of Alzheimer's disease but showed only modest or poor efficacy in rhesus monkeys and humans, respectively,[3][4] perhaps due to an array of dose-limiting side effects including increased heart rate and blood pressure, increased salivation, urinary frequency and burning upon urination, increased lacrimation and nasal secretion, abnormal accommodation, heartburn, upset stomach as well as cramps, nausea, vomiting and diarrhea, excessive sweating and palpitations.[5]

See also


  1. ^ Ensinger HA, Doods HN, Immel-Sehr AR, et al. (1993). "WAL 2014--a muscarinic agonist with preferential neuron-stimulating properties". Life Sciences. 52 (5–6): 473–80. doi:10.1016/0024-3205(93)90304-L. PMID 8441328.
  2. ^ Walland A, Burkard S, Hammer R, Tröger W (1997). "In vivo consequences of M1-receptor activation by talsaclidine". Life Sciences. 60 (13–14): 977–84. doi:10.1016/S0024-3205(97)00037-4. PMID 9121364.
  3. ^ a b Wienrich M, Meier D, Ensinger HA, et al. (April 2001). "Pharmacodynamic profile of the M1 agonist talsaclidine in animals and man". Life Sciences. 68 (22–23): 2593–600. doi:10.1016/S0024-3205(01)01057-8. PMID 11392631.
  4. ^ Terry AV, Buccafusco JJ, Borsini F, Leusch A (July 2002). "Memory-related task performance by aged rhesus monkeys administered the muscarinic M(1)-preferring agonist, talsaclidine". Psychopharmacology. 162 (3): 292–300. doi:10.1007/s00213-002-1105-3. PMID 12122487. S2CID 23323985.
  5. ^ Adamus WS, Leonard JP, Tröger W (1995). "Phase I clinical trials with WAL 2014, a new muscarinic agonist for the treatment of Alzheimer's disease". Life Sciences. 56 (11–12): 883–90. doi:10.1016/0024-3205(95)00024-Z. PMID 10188789.